Medline (NASDAQ:MDLN) Research Coverage Started at Tigress Financial

Tigress Financial assumed coverage on shares of Medline (NASDAQ:MDLN) in a research report released on Thursday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $55.00 target price on the stock.

A number of other equities analysts also recently commented on MDLN. Evercore initiated coverage on Medline in a report on Monday, January 12th. They issued an “outperform” rating and a $50.00 price objective on the stock. William Blair initiated coverage on shares of Medline in a research report on Monday, January 12th. They issued an “outperform” rating for the company. Sanford C. Bernstein began coverage on shares of Medline in a report on Monday, January 12th. They set an “outperform” rating and a $49.00 price target on the stock. JPMorgan Chase & Co. set a $55.00 price objective on shares of Medline in a research note on Wednesday, January 21st. Finally, Barclays assumed coverage on shares of Medline in a research report on Monday, January 12th. They set an “overweight” rating and a $50.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $47.92.

Medline Stock Performance

Shares of MDLN stock opened at $47.30 on Thursday. Medline has a fifty-two week low of $34.89 and a fifty-two week high of $47.99.

Insider Activity at Medline

In related news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of Medline stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $28.37, for a total value of $172,727,085.27. Following the transaction, the insider owned 4,806,160 shares in the company, valued at $136,350,759.20. This trade represents a 55.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Charles N. Mills bought 2,579,310 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were purchased at an average cost of $29.00 per share, with a total value of $74,799,990.00. Following the transaction, the director owned 2,441,379 shares in the company, valued at approximately $70,799,991. The trade was a -1,870.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Institutional Trading of Medline

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. bought a new position in Medline in the 4th quarter worth approximately $793,278,000. Baillie Gifford & Co. acquired a new stake in shares of Medline in the fourth quarter worth $437,236,000. Massachusetts Financial Services Co. MA acquired a new position in Medline during the 4th quarter valued at $429,544,000. UBS Group AG acquired a new position in Medline during the 4th quarter valued at $54,707,000. Finally, Pictet Asset Management Holding SA bought a new stake in Medline in the 4th quarter valued at $48,996,000.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.